跳至主要内容
临床试验/NCT05270902
NCT05270902招募中不适用

Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation

Medical University of Vienna2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
2
主要终点
Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)

研究概览

简要总结

To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients undergoing heart transplantation

排除标准

  • Declined informed consent
  • Age < 18 years#
  • Receiving antileukocyte drugs
  • Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
  • Ex-vivo perfusion

结局指标

主要结局

Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)

时间窗: 5 days

Difference in maximal cytokine peak levels in various cytokine levels compared to baseline measured by ELISA

次要结局

  • Mechanical Ventilation(up to 4 weeks)
  • Difference of immunosuppression (TTV)(30days)
  • 30-day mortality(30 days)
  • Difference of immunosuppression (sST2)(30days)
  • primary graft dysfunction score(7 days)
  • Delirium(5 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Martin Bernardi

Principal Investigator

Medical University of Vienna

研究点 (2)

Loading locations...

相似试验

Haemoadsorption During Heart Transplantation | 临床试验